Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study
出版年份 2021 全文链接
标题
Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study
作者
关键词
-
出版物
Future Oncology
Volume -, Issue -, Pages -
出版商
Future Medicine Ltd
发表日期
2021-09-15
DOI
10.2217/fon-2021-0568
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis
- (2021) Sara Bringhen et al. LEUKEMIA RESEARCH
- Subgroup analysis of ICARIA‐MM study in relapsed/refractory multiple myeloma patients with high‐risk cytogenetics
- (2021) Simon J. Harrison et al. BRITISH JOURNAL OF HAEMATOLOGY
- Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial
- (2021) Meletios A Dimopoulos et al. LANCET ONCOLOGY
- Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis
- (2020) Meletios A. Dimopoulos et al. LEUKEMIA
- Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
- (2020) Fredrik H. Schjesvold et al. HAEMATOLOGICA
- Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
- (2020) Michele Cavo et al. Lancet Haematology
- Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk
- (2020) Katja Weisel et al. Journal of Hematology & Oncology
- The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma
- (2019) Leo Rasche et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The Mechanism Of Action Of The Anti-CD38 Monoclonal Antibody Isatuximab In Multiple Myelmoa
- (2019) Laura Moreno et al. CLINICAL CANCER RESEARCH
- Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies
- (2019) Maria-Victoria Mateos et al. HAEMATOLOGICA
- In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab
- (2019) Djordje Atanackovic et al. LEUKEMIA
- Efficacy of isatuximab/pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA-MM high-risk cytogenetics subgroup analysis
- (2019) Simon J. Harrison et al. Clinical Lymphoma Myeloma & Leukemia
- ICARIA-MM study: efficacy analysis according to prior lines of treatment
- (2019) Sara Bringhen et al. Clinical Lymphoma Myeloma & Leukemia
- Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab
- (2019) Thomas G. Martin et al. Cells
- Daratumumab in high‐risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome
- (2019) Meera Mohan et al. BRITISH JOURNAL OF HAEMATOLOGY
- Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design
- (2019) Philippe Moreau et al. Future Oncology
- Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
- (2019) Michel Attal et al. LANCET
- Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010-2016)
- (2018) Sundar Jagannath et al. Clinical Lymphoma Myeloma & Leukemia
- Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design
- (2018) Paul G Richardson et al. Future Oncology
- Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study
- (2018) Sigrun Thorsteinsdottir et al. HAEMATOLOGICA
- Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study
- (2018) Sigrun Thorsteinsdottir et al. HAEMATOLOGICA
- Evolution of multiple myeloma treatment practices in Europe from 2014 to 2016
- (2018) Marc S. Raab et al. BRITISH JOURNAL OF HAEMATOLOGY
- Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
- (2018) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting
- (2018) Paul G. Richardson et al. Blood Cancer Journal
- Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome
- (2018) Ashley R. Paquin et al. Blood Cancer Journal
- CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma
- (2018) Fabio Morandi et al. Frontiers in Immunology
- Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
- (2017) Michel Attal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management
- (2016) S. Vincent Rajkumar AMERICAN JOURNAL OF HEMATOLOGY
- Immunotherapy
- (2016) Salma Afifi et al. ANNALS OF PHARMACOTHERAPY
- Multiple myeloma in the marrow: pathogenesis and treatments
- (2016) Heather Fairfield et al. Annals of the New York Academy of Sciences
- Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
- (2016) P. Sonneveld et al. BLOOD
- International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
- (2016) Meletios A. Dimopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Multiple Myeloma: Diagnosis and Treatment
- (2016) S. Vincent Rajkumar et al. MAYO CLINIC PROCEEDINGS
- Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Philippe Moreau et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multiple myeloma epidemiology and survival: A unique malignancy
- (2016) Dickran Kazandjian SEMINARS IN ONCOLOGY
- Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States
- (2015) Xue Song et al. CURRENT MEDICAL RESEARCH AND OPINION
- Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
- (2015) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide
- (2015) H Jiang et al. LEUKEMIA
- Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group
- (2015) J Laubach et al. LEUKEMIA
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
- (2015) Sagar Lonial et al. NEW ENGLAND JOURNAL OF MEDICINE
- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
- (2015) A. Keith Stewart et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma
- (2015) W I Gonsalves et al. Blood Cancer Journal
- SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies
- (2014) J. Deckert et al. CLINICAL CANCER RESEARCH
- Pathogenesis of Renal Failure in Multiple Myeloma: Any Role of Contrast Media?
- (2014) Michele Mussap et al. Biomed Research International
- The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies
- (2012) A Kalff et al. Blood Cancer Journal
- Multiple Myeloma
- (2011) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
- (2009) R Fonseca et al. LEUKEMIA
- Evolution and Function of the ADP Ribosyl Cyclase/CD38 Gene Family in Physiology and Pathology
- (2008) Fabio Malavasi et al. PHYSIOLOGICAL REVIEWS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started